開拓藥業有限公司*

KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9939)

VOLUNTARY ANNOUNCEMENT
RESULTS OF THE CLINICAL TRIAL OF PROXALUTAMIDE FOR THE TREATMENT OF HOSPITALISED COVID-19 PATIENTS

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the "**Company**" and together with its subsidiaries, the "**Group**") to inform the shareholders and potential investors of the Company about the latest business advancement of the Group. Reference is made to the announcement dated January 28, 2021 (the "**Announcement**"). Unless otherwise defined herein, the capitalised terms shall have the same meaning as those defined in the Announcement.

The Board of directors of the Company (the "**Board**") is pleased to release the results of the Clinical Trial of Proxalutamide for the treatment of hospitalised COVID-19 patients. In the Clinical Trial, Proxalutamide met the primary endpoint at day 14, demonstrating a reduction of 4.01 in WHO COVID-19 ordinal scale from a baseline of 5.663 to 1.653 in the Proxalutamide Arm versus a reduction of 0.25 from a baseline of 5.618 to 5.368 in the Control Arm with a p value <0.0001. Proxalutamide also demonstrated a reduction in mortality risk by 92% (3.7% vs 47.6%) and shortened median hospital length stay by 9 days (median hospital stay of 5 days vs 14 days).

The Clinical Trial is a multi-center, randomised, double-blinded, placebo-controlled parallel assignment study of Proxalutamide's treatment for hospitalised COVID-19 patients. The trial has two cohorts (men and women) and two arms (the Proxalutamide Arm and the Control Arm). It originally enrolled 588 patients who met the eligibility criteria within 48 hours of admission to hospital.

In the Proxalutamide Arm, patients were orally administered Proxalutamide 300 mg once daily (QD) for 14 days. In the Control Arm, patients were orally administered Proxalutamide placebo once daily (QD) for 14 days. Each arm will also receive standard of care as determined by the principal investigator at the site. The primary endpoint of the Clinical Trial is the treatment efficacy of Proxalutamide relative to control, as assessed by the WHO COVID-19 ordinal scale on day 14.

The preliminary analysis conducted on March 9, 2021 was based on 294 patients (56.8% male) in the Proxalutamide Arm and 296 patients (57.8% male) in the Control Arm. According to the results on day 14, the mortality in the Proxalutamide Arm was 11 (3.7%), compared to 141 (47.6%) in the Control Arm, demonstrating a reduced mortality risk of 92%. The number of new mechanical ventilation (MV) and/or death in the Proxalutamide Arm was 13 (4.4%), compared to 156 (52.7%) in the Control Arm, reducing mortality risk by 92%; and median hospital length stay (days) in the Proxalutamide Arm was 5, while it was 14 in Control Arm, which means Proxalutamide shortened hospital stay by 9 days.

	Proxalutamide Arm (n=294)		**Controlled Arm (n=296)**	
Day 14	*Number*	*(%)*	*number*	*(%)*
Mortality	11	3.7	141	47.6[(1)]
New mechanical ventilation (MV) and/or death	13	4.4	156	52.7
Hospital Length Stay (Days)	5	N/A	14	N/A
Discharged from hospital Day 14	262	89.1	97	32.8

Note:

(1) According to The Lancet, a 50% (n = 13,496) mortality rate was reported for in-hospital mortality in North Brazil (Amazonas). (Ranzani O, et al. 15 Jan 2021. The Lancet. Characterisation of the first 250 000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data. Accessed 10 March 2021.)

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that Proxalutamide will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
Executive Director

Hong Kong, March 11, 2021

As of the date of this announcement, the executive Director is Dr. Youzhi Tong; the non-executive Directors are Mr. Gang Lu, Mr. Jie Chen, Dr. Bing Chen, Mr. Wei Zhang and Ms. Yaling Wu; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* *For identification purpose only*